VIROGIN Receives FDA Fast Track Designation for VG161, a Novel Therapy Candidate for the Treatment of Advanced Hepatocellular Carcinoma

Vancouver, British Columbia, July 13, 2023 Virogin Biotech announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of VG161 for patients with advanced unresectable Hepatocellular Carcinoma. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancers and accounts for 75–90% of all primary liver cancers, […]

VG161 granted for FDA Orphan Drug Designation

Vancouver, British Columbia, February 12, 2023 Virogin Biotech announced that it has received a formal letter response from the US Food and Drug Administration (FDA) Office of Orphan Products Development, of which its Class I innovative oncolytic virus product, VG161, has been granted for treatment of Intrahepatic Cholangiocarcinoma (ICC). Intrahepatic Cholangiocarcinoma (ICC) is a rare […]

New Research Progress on VG301 Development

Virogin’s R&D team announced good news just after New Year’s Eve in 2023. Virogin’s global R&D team released the preprint of “HSV-1 Oncolytic Virus Targeting CEACAM6-Expressing Tumors Using a Bispecific T Cell Engager” on BioRxiv. This article focuses on the latest research progress of the company’s newest generation of oncolytic virus product VG301 (product code […]

Virogin Biotech Announces Dosing the First US Patient in a Phase 1 Study of VG201 for Patients With Advanced Solid Tumors

VANCOUVER, British Columbia, November 15, 2022 ( – Virogin Biotech, a clinical-stage biotech company, today announced that the first patient has been dosed in its Phase 1 clinical study evaluating VG201, a first-in-class HSV Type I oncolytic virus product constructed based on a transcriptional and translational dual-regulated (TTDR) backbone developed by Virogin Biotech. It is designed […]

Virogin Biotech Receives IND Approval from the U.S. FDA for VG201

Vancouver, Canada – Virogin Biotech, a clinical-stage biotech company is pleased to announce that their Investigational New Drug (IND) application for VG201 has been granted by the U.S. Food and Drug Administration (FDA), allowing Virogin to initiate a Phase I clinical trial of VG201. VG201 is Virogin’s first product candidate built with Transcriptional and Translational […]

Virogin Biotech Receives IND Approvals from Chinese NMPA for VG201 and VG161

Vancouver, Canada – Virogin Biotech, a clinical-stage biotech company, is pleased to announce that, on April 19, 2022, the National Medical Products Administration (NMPA), the Chinese agency for regulating drugs and medical devices, granted IND approvals for the company’s investigational drug candidates VG201 and VG161, allowing the initiation of a Phase I clinical trial of […]